Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Grenoble – page 41

658 clinical trials in Grenoble, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Grenoble at a glance
658
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

658 trials in Grenoble

Open in trial search

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Acute myeloid leukaemia

Not recruiting

Study on Venetoclax, Azacitidine, and Donor Lymphocyte Infusion for Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Relapse After Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Optic ischaemic neuropathy

Not recruiting

Study on the Effects of Bosentan for Patients with Early Stage Non-Arteritic Anterior Ischemic Optic Neuropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Bladder cancer

Not recruiting

Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Encorafenib and Binimetinib for Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Acute myeloid leukaemia+1

Not recruiting

Study of three different doses of busulfan with fludarabine and thymoglobuline in stem cell transplantation for patients with high-risk myeloid blood disorders

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Institut Paoli-Calmettes

Critical illness

Not recruiting

Study on Hydrocortisone and Fludrocortisone for Adults with Critical Illness-Related Corticosteroid Insufficiency

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tetracosactide
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary hypertension

Not recruiting

Study on the Effects of Riociguat and Macitentan in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell leukaemia

Not recruiting

Study on Daratumumab, Lenalidomide, and Dexamethasone for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Assistance Publique Hopitaux De Paris

Hepatocellular carcinoma

Not recruiting

Study on Nivolumab with Drug Combination for Patients with Intermediate Stage Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:The Clatterbridge Cancer Centre NHS Foundation Trust

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Ribociclib and Letrozole for Patients with High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:Solti Group

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Grenoble

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on head and neck cancers, multiple myeloma, and various types of leukemia. Studies evaluate novel combination therapies and targeted treatments for improved patient outcomes.

  • Advanced NSCLC Treatment Studies
  • Gastric Cancer Immunotherapy
  • Hematologic Malignancies

Innovative approaches combining immunotherapy with standard treatments are showing promise in treating various forms of cancer.

02 Transplant Medicine

Clinical investigations examining kidney transplant outcomes and rejection prevention. Research focuses on new therapeutic approaches for managing transplant-related complications.

  • Antibody-Mediated Rejection
  • Novel Immunosuppression Strategies
  • Long-term Graft Survival

Studies aim to improve transplant success rates and reduce rejection incidents through innovative medication protocols.

03 Neurological Disorders

Research into narcolepsy and multiple sclerosis treatments, evaluating new therapeutic approaches for better symptom management and disease control.

  • Sleep Disorder Management
  • MS Treatment Innovations
  • Neurological Disease Progression

Cutting-edge treatments being developed to address both rare and common neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.